Home
The Company
Technology Development
Our Strategy
Medical Applications
Non Medical Applications
Contact

Our Strategy - Medical

The Opportunity

In the multi-billion dollar biomedical imaging market, there is an ongoing race to develop a new standard of imaging technology capable of even earlier disease detection, which is affordable to implement, comfortable for patients, and delivers diagnostic images and data in a timely manner.

A major opportunity exists for a break-though imaging technology in the following fields:

  1. Early detection of breast and prostate cancer;
  2. Carotid arteries;
  3. Deep anatomical targets;
  4. Pharmaceutical research and development.

InnerVision has developed and is now striving to commercialize just such a technology.

The Current Technology Gap

Mature imaging players in the biomedical market have self diagnosed the weaknesses of mammography x-rays in terms of reliability of resolution for disease detection and patient comfort and acceptance. Use of traditional high resolution ultrasound in screening has been inhibited by the expense related to time required to capture a meaningful image and the need for very skilled clinicians to operate the equipment.

InnerVision's technology is a paradigm shift that is intended to resolve the issues of x-ray and current ultrasound technology, not only for mammography, but also in screening of prostate cancer.

Value Proposition

In-vivo & Instantaneous
High spatial & contrast resolution – sensitivity and specificity
Flexible, adaptable & scalable architecture with high throughput
Data suites and volumetric information
Safe & intuitive – external, non invasive with low frequency
Screening & diagnosis – all in one
Reduce false positive & false negative
Ability to differentiate tissues with high confidence
Can image through dense media, e.g., dense breasts, external prostate, bone…
Can simultaneously handle a variety of applications from one central location
Low operator skill dependency

The Business Model

InnerVision will be a provider of enabling technology to third parties who are well positioned to penetrate the various medical market segments.

Conceptually, the current strategy is as follows:

  • InnerVision will be a "Science" company, in the business;
    • Not the supplier of capital equipment for clinics (no production, manufacturing or distribution);
    • Not operating the clinics.
  • Under this technology licensing strategy:
    • Licensees distribute the technology embedded in their own proprietary products.
  • The primary sources of InnerVision revenue will be:
    • License Fees/Royalties

We believe that ultimate adoption of our technology will be greater by placing the roll out of the device and the patient interface in the hands of those with well established production, and distribution and marketing expertise.

Our Strategy
FLASH ULTRASOUND Enabling new standards for diagnosis.